In India, erectile dysfunction following prostate ablative therapy is managed by urologists. Erectile dysfunction is the persistent inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance, driven in most adult men by impaired nitric-oxide-mediated relaxation of the cavernosal smooth muscle and reduced penile arterial inflow. The Massachusetts Male Aging Study (Feldman 1994) and the 2001-2002 NHANES analysis (Selvin 2007) found prevalence rising from about 5% at age 40 to nearly 70% by age 70, with roughly 18 million US men affected.
Erectile dysfunction (ICD-10: N52) is defined by the AUA and the EAU as the consistent or recurrent inability to attain or maintain a penile erection sufficient for satisfactory sexual performance, present for at least three months. The physiology of erection requires intact arterial inflow, venous occlusion within the corpora cavernosa, neural signalling via the pelvic parasympathetic plexus, and a permissive hormonal milieu. Sexual stimulation triggers nitric oxide release from cavernous nerves and endothelium; nitric oxide activates guanylate cyclase to raise cyclic GMP, which relaxes trabecular smooth muscle, expands the sinusoidal spaces, and compresses subtunical venules to trap blood. Phosphodiesterase type 5 degrades cyclic GMP and ends the erection — the target of all oral PDE5 inhibitors.
The key symptoms of Erectile dysfunction following prostate ablative therapy are: Difficulty achieving an erection during sexual activity on more than 50% of attempts over the prior three months — the validated definition used in the IIEF-5 / SHIM questionnaire., Inability to maintain an erection long enough for satisfactory intercourse, with the penis becoming detumescent before or during penetration., Erection that is incomplete or insufficiently rigid for penetration despite normal sexual desire and arousal — distinguishing ED from low libido., Loss of the morning (nocturnal) erections that healthy men typically experience 3-5 times per night during REM sleep — a useful pointer toward organic rather than psychogenic disease., Reduced or absent response to visual or tactile sexual stimulation, often with shorter duration of any erection that does occur., Coexisting reduced sexual desire, ejaculatory changes, or premature ejaculation in 30-40% of men with ED — symptoms cluster more often than they occur alone., Onset that is gradual over months to years in organic vasculogenic ED, versus abrupt situational onset with preserved morning erections in psychogenic ED..
Diagnosis of erectile dysfunction begins with a focused sexual, medical, and psychosocial history, supplemented by a validated questionnaire such as the IIEF-5 (Sexual Health Inventory for Men, SHIM). The AUA 2018 guideline and EAU 2021 update both recommend the IIEF-5 as the initial standardised assessment; scores below 22 indicate ED, with severity graded by score band. History should establish onset (gradual versus abrupt), presence of nocturnal erections, situational versus global pattern, libido, ejaculatory function, partner factors, and a full medication review. Physical examination focuses on cardiovascular status (blood pressure, peripheral pulses, signs of metabolic syndrome), secondary sex characteristics, genital examination for testicular volume, penile plaques (Peyronie's), and a digital rectal examination in men over 40. First-line laboratory testing is targeted: fasting glucose or HbA1c, lipid panel, and an 8-10 a.m. total testosterone in men with low libido, fatigue, or examination findings suggesting hypogonadism; prolactin, LH, FSH, and free testosterone are reserved for confirmed low total testosterone. Most men with typical ED do not require specialised vascular or neurological testing — empiric trial of a PDE5 inhibitor in correctly counselled patients is both diagnostic and therapeutic. Penile duplex Doppler ultrasound with intracavernosal vasoactive injection is the gold-standard vascular test, reserved for men who fail PDE5 inhibitors, are considering surgical implants, have a history of pelvic trauma, or have legal-medical indications. Nocturnal penile tumescence and rigidity monitoring (RigiScan) distinguishes psychogenic from organic ED but is rarely used outside research and forensic settings. Because ED is an early marker of generalised vascular disease, ACC/AHA-style global cardiovascular risk assessment is recommended in every man at diagnosis, and men with multiple risk factors should be evaluated for occult coronary disease per the Princeton III consensus.
Erectile dysfunction is highly treatable in the majority of men. With first-line PDE5 inhibitor therapy at optimal dose and timing, 60-80% return to satisfactory intercourse, and a further 15-20% respond to second-line injection or vacuum therapy. Approximately 90-95% of men who proceed to inflatable penile prosthesis report satisfaction with the result in long-term series (Carson 2011 and subsequent cohorts). Prognosis varies by mechanism: psychogenic and post-prostatectomy ED have the greatest potential for recovery, while ED from advanced diabetes, severe atherosclerosis, or complete cavernous nerve transection is least reversible. Importantly, ED is now recognised as an independent predictor of major adverse cardiovascular events — the 2013 Vlachopoulos meta-analysis (36,744 men, 7.5 years follow-up) showed ED carried a 44% increase in total cardiovascular events, a 25% increase in all-cause mortality, and a 19% increase in coronary heart disease. Effective ED treatment, combined with aggressive management of cardiovascular risk factors, sleep apnea, diabetes, and depression, improves both sexual outcomes and overall longevity. Most men can expect to remain sexually active into their 70s and 80s with appropriate treatment.
Refer to a urologist or sexual medicine specialist when PDE5 inhibitors fail or are not tolerated at maximum dose, when intracavernosal injection or a penile prosthesis is being considered, when ED follows pelvic surgery or radiotherapy and rehabilitation is needed, when Peyronie's disease coexists, when there is suspected hypogonadism requiring confirmation and replacement, or when ED occurs in a young man after pelvic trauma where revascularisation may be appropriate. Primary care manages most uncomplicated ED effectively after structured cardiovascular and metabolic workup.
Find specialists →PDE5 inhibitor benefit is evident on the first appropriately timed dose; an adequate trial requires at least 4-6 attempts at the maximum tolerated dose before declaring non-response. Intracavernosal injection therapy requires an in-clinic test dose and 1-2 follow-up titration visits over 2-4 weeks. Inflatable penile prosthesis surgery is a day-case or single-overnight admission; the device is activated 4-6 weeks after implantation, with full sexual activity from 6-8 weeks. Post-prostatectomy penile rehabilitation aims for recovery of spontaneous erections over 12-24 months; daily or on-demand PDE5 inhibitors plus vacuum therapy are started early after surgery. Lifestyle interventions — weight loss, exercise, smoking cessation — show measurable improvement in IIEF-5 scores by 3-6 months and continued gains at 12 months.
Regular aerobic exercise is one of the most reliable lifestyle interventions for ED. Aim for 150-300 minutes of moderate-intensity activity each week (brisk walking, swimming, cycling, jogging) plus two resistance sessions. Pelvic floor (Kegel) exercises can be added — twelve weeks of structured training improves IIEF scores in mild ED and aids post-prostatectomy recovery. Cyclists should consider saddle design and posture if symptoms correlate with perineal pressure. Exercise capacity also matters for safety — men who cannot achieve at least 3-5 metabolic equivalents (climbing two flights of stairs without symptoms) should have cardiac assessment before resuming sexual activity.
Look for board certification in urology, fellowship training or recognised experience in sexual medicine, comfort with penile duplex Doppler ultrasound, and a high-volume penile prosthesis practice (more than 25 implants per year) if surgery is being considered. Ask whether the practice offers structured post-prostatectomy penile rehabilitation, whether it routinely screens for cardiovascular risk at the ED consultation, and how it manages prosthesis infection prevention. Continuity matters — ED management often spans years and requires iterative adjustment.
Medically reviewed by AIHealz Medical Editorial Board · May 12, 2026
Ranked by patient outcomes and specialized experience.
Specialists who treat Erectile dysfunction following prostate ablative therapy. Get expert guidance and personalized care.